Cetuximab
About
Therapy type: Targeted therapy
Therapy strategy: EGFR inhibition
Mappings
NCI Thesaurus: Cetuximab (coding:ncit:C1723)
RxNorm: cetuximab (coding:rxcui:318341, coding:omop:4247978)
SNOMED: Cetuximab (coding:sctid:409400001, coding:omop:1315411)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) HC (1) | EGFR positive, Wild type KRAS | Colorectal Adenocarcinoma | Cetuximab, Fluorouracil, Irinotecan | |
| FDA (1) HC (1) | EGFR positive, Wild type KRAS | Colorectal Adenocarcinoma | Cetuximab, Irinotecan | |
| FDA (1) HC (2) | EGFR positive, Wild type KRAS | Colorectal Adenocarcinoma | Cetuximab | |
| FDA (2) HC (1) | BRAF p.V600E | Colorectal Adenocarcinoma | Cetuximab, Encorafenib | |
| FDA (1) | KRAS p.G12C | Colorectal Adenocarcinoma | Adagrasib, Cetuximab | |
| FDA (1) HC (1) | BRAF p.V600E | Colorectal Adenocarcinoma | Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin | |
| FDA (1) | BRAF p.V600E | Colorectal Adenocarcinoma | Cetuximab, Encorafenib, Fluorouracil, Irinotecan |